Gene-tobacco carcinogen interactions and lung cancer risk - a novel approach for precision cancer prevention
Gene-tobacco carcinogen interactions and lung cancer risk - a novel approach for precision cancer prevention
批准号:
10581340
负责人:
Philip Lazarus
金额:
$66.8万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-12-16 至 2027-11-30
关键词:
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone7alpha hydroxylaseAllelesAsianBiological MarkersBlack raceBlood specimenCancer BurdenCancer EtiologyCarcinogensCellsCessation of lifeChemopreventive AgentChineseCohort StudiesCommunitiesComplexCopy Number PolymorphismCytochrome P450CytosolDataDevelopmentDrug Metabolic DetoxicationEnzymesExhibitsGenesGenetic MarkersGenetic PolymorphismGenetic VariationGenotypeGlucuronidesGlucuronosyltransferaseGoalsHealthHumanIsomerismLiverLungMalignant neoplasm of lungMediatingMetabolicMetabolismMicrosomesNicotineNitrosaminesOxidoreductasePathway interactionsPatternPhenotypePlayPopulationPredispositionPrevention strategyProspective cohortProspective, cohort studyProtein IsoformsRiskRoleSNP genotypingSingaporeSmokerSmokingTissuesTobaccoTobacco smokeTobacco-Associated CarcinogenUrineValidationVariantWomen&aposs Healthcancer riskcarcinogenesiscarcinogenicitycigarette smokingcohortcost effectiveenantiomergenetic variantgenome wide association studygenome-widehigh riskimprovedinsightlung cancer preventionlung cancer screeninglung carcinogenesislung developmentmortalitynovelnovel strategiesphenotypic biomarkerprecision cancer preventionprospectiveprotective pathwayrecruitsample collectionscreeningsmoking cessationtargeted sequencingurinary
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The tobacco-specific nitrosamine (TSNA), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), is considered
a major contributor to the induction of lung cancer in smokers. The metabolism of NNK is complex with its
carcinogenic effects likely via the formation of its major pro-carcinogenic metabolite, 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanol (NNAL). Two enantiomers of NNAL are formed: (R)- and (S)-NNAL, both of which are
extensively detoxified by glucuronidation in humans. Our novel preliminary data demonstrate a strong and
statistically significant inverse association between the ratio of urinary (R)-NNAL-glucuronide (Gluc)/(S)-NNAL-
Gluc and lung cancer risk in two independent prospective cohort studies. Furthermore, smokers homozygous
for the deletion polymorphism of the major NNAL-glucuronidating enzyme, UGT2B17, had a significant 3-fold
higher risk for lung cancer than those with at least one functional UGT2B17 allele in both cohorts. These data
strongly support our hypothesis that (R)-NNAL plays a key role in tobacco-induced lung carcinogenesis and
suggests that we have identified novel important phenotypic and genetic markers of lung cancer risk. The goal
of this proposal is to evaluate the importance of NNAL enantiomers and glucuronides in lung cancer
carcinogenesis, and to elucidate novel phenotypic and genetic markers of NNAL formation and elimination
pathways and lung cancer risk in multiple populations. Our goals are to prospectively evaluate whether the
levels or ratios of specific urinary NNAL isomers or glucuronides are associated with lung cancer risk in: (1)
Chinese smokers from three cohort studies from Shanghai and Singapore, and (2) White and Black smokers
from the Southern Community Cohort Study, and to subsequently screen and validate genetic variants
associated with the variability in NNAL enantiomer and glucuronide formation. These studies should provide
crucial insight for understanding variability and establishing phenotypes and genotypes important in lung
cancer risk and will assist in identifying smokers at high risk for lung cancer for the development of
chemopreventive strategies targeting the NNK metabolism pathway.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The UGT2A and 3A metabolizing enzymes and tobacco-related cancer risk
-
批准号:9131748
-
项目类别:
-
资助金额:$45.97万
-
财政年份:2015
-
负责人:Philip Lazarus
-
依托单位:
The UGT2A and 3A metabolizing enzymes and tobacco-related cancer risk
-
批准号:9221216
-
项目类别:
-
资助金额:$5.21万
-
财政年份:2015
-
负责人:Philip Lazarus
-
依托单位:
The UGT2A and 3A metabolizing enzymes and tobacco-related cancer risk
-
批准号:9278174
-
项目类别:
-
资助金额:$62.66万
-
财政年份:2015
-
负责人:Philip Lazarus
-
依托单位:
Role of pharmacogenetics on exemestane metabolism and toxicity
-
批准号:8727490
-
项目类别:
-
资助金额:$44.58万
-
财政年份:2012
-
负责人:Philip Lazarus
-
依托单位:
Role of pharmacogenetics on exemestane metabolism and toxicity
-
批准号:8915094
-
项目类别:
-
资助金额:$46.6万
-
财政年份:2012
-
负责人:Philip Lazarus
-
依托单位:
Role of pharmacogenetics on exemestane metabolism and toxicity
-
批准号:8372081
-
项目类别:
-
资助金额:$52.73万
-
财政年份:2012
-
负责人:Philip Lazarus
-
依托单位:
Role of pharmacogenetics on exemestane metabolism and toxicity
-
批准号:8527745
-
项目类别:
-
资助金额:$51.33万
-
财政年份:2012
-
负责人:Philip Lazarus
-
依托单位:
UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK
-
批准号:7265009
-
项目类别:
-
资助金额:$47.42万
-
财政年份:2007
-
负责人:Philip Lazarus
-
依托单位:
UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK
-
批准号:7612146
-
项目类别:
-
资助金额:$49.78万
-
财政年份:2007
-
负责人:Philip Lazarus
-
依托单位:
UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK
-
批准号:8064730
-
项目类别:
-
资助金额:$50.27万
-
财政年份:2007
-
负责人:Philip Lazarus
-
依托单位:
UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK
-
批准号:7809628
-
项目类别:
-
资助金额:$50.77万
-
财政年份:2007
-
负责人:Philip Lazarus
-
依托单位:
UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK
-
批准号:7407387
-
项目类别:
-
资助金额:$48.31万
-
财政年份:2007
-
负责人:Philip Lazarus
-
依托单位:
UDP GLUCURONOSYLTRANSFERASES, DETOXIFICATION OF NNK
-
批准号:6573852
-
项目类别:
-
资助金额:$31.56万
-
财政年份:2002
-
负责人:Philip Lazarus
-
依托单位:
UDP GLUCURONOSYLTRANSFERASES, DETOXIFICATION OF NNK
-
批准号:6666289
-
项目类别:
-
资助金额:$31.56万
-
财政年份:2002
-
负责人:Philip Lazarus
-
依托单位:
UDP GLUCURONOSYLTRANSFERASES, DETOXIFICATION OF NNK
-
批准号:6444609
-
项目类别:
-
资助金额:$31.56万
-
财政年份:2001
-
负责人:Philip Lazarus
-
依托单位:
UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK
-
批准号:6379921
-
项目类别:
-
资助金额:$21.57万
-
财政年份:2000
-
负责人:Philip Lazarus
-
依托单位:
UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK
-
批准号:6127911
-
项目类别:
-
资助金额:$21.57万
-
财政年份:2000
-
负责人:Philip Lazarus
-
依托单位:
UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK
-
批准号:6640803
-
项目类别:
-
资助金额:$16.07万
-
财政年份:2000
-
负责人:Philip Lazarus
-
依托单位:
UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK
-
批准号:6516548
-
项目类别:
-
资助金额:$21.57万
-
财政年份:2000
-
负责人:Philip Lazarus
-
依托单位:
UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK
-
批准号:6876789
-
项目类别:
-
资助金额:$6.02万
-
财政年份:2000
-
负责人:Philip Lazarus
-
依托单位:
海外基金